Ignatova G L, Antonov V N
South Ural State Medical University, Ministry of Health of Russia, Department of Therapy, Chelyabinsk, Russia.
Ter Arkh. 2018 Aug 27;90(8):53-62. doi: 10.26442/terarkh201890853-62.
The article uses the analysis of clinical and pharmacoeconomic effectiveness of 13-valent conjugated pneumococcal vaccine in patients with combined course of chronic obstructive pulmonary disease (COPD), ischemic heart disease (IHD) and chronic heart failure (CHF).
429 male patients with diagnoses of COPD, IHD, CHF were included in the study. The main endpoints of observation, for 5 years, for evaluation of effectiveness were dynamic assessment for class CHF, the number of exacerbations, hospitalizations, the number of pneumonias. The 13-valent conjugated pneumococcal vaccine (PCV13) Prevenar-13 was used for vaccine prophylaxis.
The increase in age with the combined course of COPD and cardiovascular pathology leads to a deterioration in the basic clinical and functional indicators. With the increase in the clinical symptoms of the defeat of the respiratory system. There is an increase in the functional class of heart failure. Inclusion of vaccine prophylaxis PCV13 in the management plan of patients with combined pathology. Reduce the degree of dyspnea and stabilize the main functional indicators.
Vaccination of patients with COPD using PCV13 combined with CHF and IHD made it possible to manage the health system expenses by 74-84%.
本文对13价肺炎球菌结合疫苗用于慢性阻塞性肺疾病（COPD）、缺血性心脏病（IHD）和慢性心力衰竭（CHF）合并症患者的临床及药物经济学效果进行分析。
本研究纳入了429例诊断为COPD、IHD、CHF的男性患者。观察的主要终点为5年内对有效性的评估，包括CHF分级的动态评估、急性加重次数、住院次数、肺炎次数。采用13价肺炎球菌结合疫苗（PCV13）沛儿13进行疫苗预防。
COPD与心血管疾病合并症患者年龄增加会导致基本临床和功能指标恶化。随着呼吸系统受累临床症状的加重，心力衰竭功能分级增加。在合并症患者的管理计划中纳入PCV13疫苗预防，可减轻呼吸困难程度并稳定主要功能指标。
使用PCV13对COPD合并CHF和IHD患者进行疫苗接种，可使卫生系统费用降低74%至84%。
